Source link : https://newshealth.biz/health-news/next-gen-bcl2-inhibitor-approved-for-aggressive-lymphoma/
The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma. A next-generation product in the drug class, sonrotoclax is indicated for adults previously treated with two or more lines of therapy that includes a Bruton’s […]
The post Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-13 21:21:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8